Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2019

View Archived Issues

Inducing HER2 expression to sensitize tumors

Size matters for cell prowess

T cells ChAT with blood vessels via neurotransmitter

Debiopharm initiates phase II FUZE study of Debio-1347

Vertex presents positive phase III study data for tezacaftor/ivacaftor

Advaxis initiates phase I/II study of ADXS-503 in patients with NSCLC

Phase III studies of brexpiprazole in patients with bipolar I disorder do not meet primary endpoint

KA-11 demonstrates promising activity in preclinical models of epilepsy and pain

MELK as a novel therapeutic target for neuroblastoma

University of Utah, Stingray Therapeutics patent E-NPP 1 inhibitors/STING modulators

ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors

New PAI-1 inhibitors presented by Eastern Michigan University and the University of Michigan

IL-13Ralpha2 as a novel marker and potential therapeutic target for malignant melanoma

The Helleday Foundation describes ADP-sugar pyrophosphatase inhibitors

New selective estrogen receptor degradation inducers patented by Zeno Royalties & Milestones

Loss of miR-7 facilitates gastric cancer metastasis: a potential biomarker and therapeutic target

TRIM14 promotes tumor invasion in glioblastoma, and may be a novel therapeutic target

AbCellera Biologics and Novartis enter multitarget collaboration

Forbius enters collaboration to evaluate TGF-beta inhibitor in myelofibrosis

Kymab begins phase I/II study of KY-1044 and atezolizumab in advanced cancers

PellePharm initiates phase III study of patidegib topical gel in basal cell nevus syndrome

Transgenic mouse model allows differentiation of platelet and leukocyte functions

ApoE-complement link opens door for new targets in Alzheimer's, atherosclerosis

New 64-week data reported from phase III study of Crysvita in X-linked hypophosphatemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.